GLSI
NASDAQ · Biotechnology
Greenwich Lifesciences Inc
$26.81
+1.13 (+4.40%)
Financial Highlights (FY 2025)
Revenue
64.12M
Net Income
10.06M
Gross Margin
41.5%
Profit Margin
15.7%
Rev Growth
-9.0%
D/E Ratio
0.70
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 41.5% | 41.5% | 41.5% |
| Operating Margin | 20.0% | 21.2% | 20.0% |
| Profit Margin | 15.7% | 14.3% | 15.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Gross Profit | 26.60M | 26.09M | 24.79M |
| Operating Income | 12.84M | 13.31M | 11.93M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Gross Margin | 41.5% | 41.5% | 41.5% |
| Operating Margin | 20.0% | 21.2% | 20.0% |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| Rev Growth | -9.0% | -7.6% | +0.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 203.23M | 168.97M | 188.34M |
| Total Equity | 288.94M | 308.57M | 281.56M |
| D/E Ratio | 0.70 | 0.55 | 0.67 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |